An open-label study comparing a steroid sparing versus a standard steroid regimen in combination with CellCept [mycophenolate mofetil], Zenapax [daclizumab] and sirolimus in the prevention of acute renal allograft rejection.

Trial Profile

An open-label study comparing a steroid sparing versus a standard steroid regimen in combination with CellCept [mycophenolate mofetil], Zenapax [daclizumab] and sirolimus in the prevention of acute renal allograft rejection.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Daclizumab; Mycophenolate mofetil; Prednisolone; Sirolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 Feb 2010 Actual initiation date (Apr 2006) added as reported by Roche record.
    • 23 Mar 2008 Updated study design, study control, and descriptor, from Roche record.
    • 30 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top